Introduction

NAFDAC has placed products marketed by Mofus Nigeria Ltd under heightened regulatory scrutiny, issuing a watchlist pending a formal investigation into alleged non-compliance and potential misrepresentation. The action affects distributors, healthcare providers, and consumers nationwide.

What Happened

The National Agency for Food and Drug Administration and Control announced it had identified significant regulatory non-compliance involving products linked to Mofus Nigeria Ltd, Ayrtons Saunders Ltd of the UK, and Pharmaserve (North West) Ltd. Following the findings, NAFDAC activated a formal investigation under reference number NAFDAC/PMS/2026/0029, initiated continuous surveillance of the affected items, and issued notifications to relevant stakeholders.

Why This Matters

This watchlist serves as a critical safeguard for public health, signaling that the affected products may not meet established safety or quality standards. For pharmacy chains, medical distributors, and practicing clinicians, the advisory reinforces the importance of sourcing from licensed channels and maintaining strict distribution records. Consumers are encouraged to purchase medicines only from authorised outlets and remain vigilant for any signs of substandard or counterfeit items.

Key Takeaways

  • NAFDAC's watchlist is active pending the conclusion of reference number NAFDAC/PMS/2026/0029.
  • Stakeholders including distributors, pharmacists, and healthcare facilities have been formally notified to cooperate with the ongoing investigation.
  • The public should procure medical products exclusively from licensed and authorised suppliers to ensure traceability.
  • Healthcare professionals and consumers are urged to report any suspected substandard or falsified medicines to the nearest NAFDAC office immediately.
  • Maintaining complete distribution records is recommended to support regulatory traceability efforts.

Conclusion

NAFDAC's decision to watchlist Mofus Nigeria Ltd products underscores its commitment to protecting public health through rigorous regulatory oversight. As the investigation progresses, all stakeholders are advised to stay informed, comply with the agency's directives, and report any quality concerns promptly. Continued vigilance will be essential to preserving medicine safety and efficacy across the Nigerian market.